Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections

被引：391
|
作者：
Steenbergen, JN [1 ]
Alder, J [1 ]
Thorne, GM [1 ]
Tally, FP [1 ]
机构：
[1] Cubist Pharmaceut Inc, Lexington, MA 02421 USA
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2005年 / 55卷 / 03期
关键词：
MRSA; cSSSI; vancomycin;
D O I：
10.1093/jac/dkh546
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Infections caused by drug-resistant pathogens are on the rise. Daptomycin, a cyclic lipopeptide with activity against most Gram-positive pathogens, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus, is a newly US-FDA approved antimicrobial for complicated skin and skin structure infections (cSSSI). Daptomycin has a unique mechanism of action that results in destruction of the membrane potential. The rapid bactericidal activity of daptomycin makes it an attractive antibiotic for serious Gram-positive infections.
引用
收藏
页码：283 / 288
页数：6
相关论文
共 50 条
  • [31] Linezolid: a new antibiotic for gram-positive infections
    Wilson, P
    [J]. HOSPITAL MEDICINE, 2001, 62 (11): : 682 - 686
  • [32] Daptomycin therapy for invasive Gram-positive bacterial infections in children
    Ardura, Monica I.
    Mejias, Asuncion
    Katz, Kathy S.
    Revell, Paula
    McCracken, George H., Jr.
    Sanchez, Pablo J.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2007, 26 (12) : 1128 - 1132
  • [33] Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections
    Gonzalez-Ruiz, Armando
    Seaton, R. Andrew
    Hamed, Kamal
    [J]. INFECTION AND DRUG RESISTANCE, 2016, 9 : 47 - 58
  • [34] Daptomycin is safe and effective for the treatment of gram-positive cocci infections in solid organ transplantation
    Len, O.
    Montejo, M.
    Cervera, C.
    Farinas, M. C.
    Sabe, N.
    Ramos, A.
    Cordero, E.
    Torre-Cisneros, J.
    Martin-Davila, P.
    Azanza, J. R.
    Pahissa, A.
    Gavalda, J.
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2014, 16 (04) : 532 - 538
  • [35] Safety and Efficacy of Daptomycin in the Treatment of Gram-Positive Pathogens
    Kelesidis, Theodoros
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2011, 3 : 403 - 414
  • [36] Telavancin: a novel lipoglycopeptide for serious Gram-positive infections
    Laohavaleeson, Somvadee
    Kuti, Joseph L.
    Nicolau, David P.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (03) : 347 - 357
  • [37] Optimizing outcomes in patients with serious Gram-positive infections
    Miro, J. M.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 : 1 - 4
  • [38] Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia
    Rubinstein, Ethan
    Corey, G. Ralph
    Stryjewski, Martin E.
    Kanafani, Zeina A.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (17) : 2737 - 2750
  • [39] Telavancin: An antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections
    Leonard, Steven N.
    Rybak, Michael J.
    [J]. PHARMACOTHERAPY, 2008, 28 (04): : 458 - 468
  • [40] Quinupristin/dalfopristin - a novel approach for the treatment of serious Gram-positive infections - Preface
    Wood, M
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 : III - III
12345